Technical Articles

In the field of tumor immunology research, cancer-testis antigens have emerged as highly attractive targets for immunotherapy due to their unique expression pattern—highly expressed in various tumor tissues while restricted to immune-privileged testicular tissues in normal organs.

Ovarian cancer, as the most lethal type of gynecological malignancy, is mostly diagnosed in the advanced stage and is prone to developing chemotherapy resistance. In recent years, immunotherapy has brought new hope to patients with advanced ovarian cancer, especially T cell-based adoptive immunotherapy and vaccine strategies. However, how to accurately identify and amplify T cells that can specifically recognize ovarian cancer-related antigens has become a key scientific issue in this field. MHC tetramer technology, as the "gold standard" for antigen-specific T cell detection, is gradually becoming an important tool for exploring the immune response mechanism of ovarian cancer and optimizing immunotherapy regimens.

MHC tetramer technology, a revolutionary tool in immunology, has fundamentally transformed the paradigm of tumor immune monitoring and therapeutic strategy development through direct visualization of antigen-specific T cells. This review systematically examines the technical principles of MHC tetramers, their pivotal applications in tumor immunology research, breakthrough advancements in novel tetramer technologies, and their prospects for clinical translation.